Theralase Technologies Inc. V.TLT

Can’t believe some folks sold on today’s news!

[livermore2]

The price recovery definitely paints it was a shake.

Put this one away for a year or two - just like wine, it should get better with age!

[Rumpl3StiltSkin]

Gotta love the price/volume action today. Technicals finally looking proper.

[Pandora]

Yep, been doing that for 6 years now! Drank all my wine and more in the meantime! :-))

[ACEJackSuited]

This post has been removed in accordance with Community Policy

[gojotv!]

Anyone who isn't ecstatic to see a 45% "complete response" rate PLUS a 22% "partial response" rate PLUS 22% more "to be determined"... Must be allergic to money. Anyone who sold... *smh Pull your "stop losses, boys and girls, the manipulators are out and this is their last chance for cheap shares! Don't let 'em get yours! (IMNSHO, of course! lol)

[enriquesuave]

We have to beat the competition by a nice margin to be number one and that IMO should not be too hard given that the present competition single agents is 17%CR for Vicinium, 19%CR for Keytruda, and 24% CR for Adstiladrin.  We have the potential to make these look like placebos IMO, however we still need more data and for sure we will be able to tell after the next 11 patients are treated. As

[CancerSlayer]

Enrique wrote: "We have to beat the competition by a nice margin to be number one and that IMO should not be too hard given that the present competition single agents is 17%CR for Vicinium, 19%CR for Keytruda, and 24% CR for Adstiladrin.  We have the potential to make these look like placebos IMO, however we still need more data and for sure we will be able to tell after the next 11

[CancerSlayer]

  Might as well add that our 8-10X "fewer" treatments could also translate into greater treatment compliance as well as happier patients : )...

[Rumpl3StiltSkin]

Should also have the backing of the insurance industry. Even though the $$ cost of each treatment will be much higher. :-)

[CancerSlayer]

  Though per treatment cost may be higher, I anticipate our full treatment course will end up costing at least 60% less imo.  Assuming comparable efficacy, HHS in the US (& ultimately Insurers) will generally go to the lowest bidder.

[Rumpl3StiltSkin]

Yep, And we should also win out in safety profile, partly due to the many fewer treatments.